Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 12:29 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 434 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Retinal Vascular Disorders Clear all

Conditions: Central Retinal Artery Occlusion
Interventions: KUS121 high dose, KUS121 low dose, Sham procedure; Drug
Lead sponsor: Kyoto Drug Discovery and Development Co., Ltd.; Industry
Eligibility: 20 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 11
States / cities: Encino, California • Huntington Beach, California • Oakland, California + 8 more

Conditions: Amyotrophic Lateral Sclerosis (ALS), Angina, Stable, Anxiety, Asthma, Atrial Fibrillation, Cancer Brain, Cancer, Breast, Cancer Colon, Cancer, Lung, Cancer, Ovarian, Cancer Prostate, Cancer Skin, Throat Cancer, Lymphoma, Cancer, Thyroid, Cancer, Other, Cerebral Palsy, Chronic Fatigue Syndrome, Cluster Headache, Chronic Obstructive Pulmonary Disease (COPD), Chronic Kidney Diseases, Crohn Disease, Deafness, Depression, Diabetes, Eczema, Epilepsy, Fibroids, Fibromyalgia, Heart Failure, Hypertension, Hyperthyroidism, Hypothyroidism, Irritable Bowel Syndrome (IBS), Infertility, Lyme Disease, Macular Degeneration, Migraine, Multiple Allergies, Multiple Sclerosis, Osteoarthritis, Osteoporosis, Ovarian Cysts, Parkinson Disease, Phantom Limb Pain, Psoriasis, Post Traumatic Stress Disorder (PTSD), Rheumatoid Arthritis, Sjogrens Disease, Spinal Cord Injury, Spinal Stenosis, Stroke, Tension Headache, Tinnitus, Ulcerative Colitis
Interventions: Advanced multi-component meditation practice; Behavioral
Lead sponsor: Tobias Moeller-Bertram; Industry
Eligibility: 21 Years and older
Enrollment: 3,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Palm Desert, California

Conditions: Neovascular Age Related Macular Degeneration
Interventions: Physician-guided diagnostic; Procedure
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 5
States / cities: Bel Air, Maryland • Bethesda, Maryland • Columbia, Maryland + 2 more

Conditions: Von Hippel-Lindau Syndrome
Interventions: Ranibizumab; Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Retinal Vein Occlusion
Interventions: AKB-9778; Drug
Lead sponsor: Aerpio Therapeutics; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Retinal Vein Occlusion, Macular Edema
Interventions: Intravitreal injection of bevacizumab, Intravitreal injection of ranibizumab (0.5 mg per dose); Drug
Lead sponsor: Barnes Retina Institute; Other
Eligibility: 50 Years and older
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Retinopathy
Interventions: Conjunctival and nasopharyngeal swabs; Other
Lead sponsor: Prism Vision Group; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: Edison, New Jersey

Conditions: Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
Interventions: AR-13503 Implant 10.6 Dose, AR-13503 Implant 21.2 Dose, AR-13503 42.4 Dose, AR-13503 63.6 Dose; Drug
Lead sponsor: Aerie Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 6
States / cities: Gilbert, Arizona • Beverly Hills, California • Walnut Creek, California + 3 more

Conditions: Diabetic Macular Edema, Retinal Disease, Macular Edema, Diabetes Mellitus, Diabetic Retinopathy, Retinal Degeneration, Retinal Diseases, Eye Diseases, Edema
Interventions: Aflibercept, foselutoclax; Drug
Lead sponsor: Unity Biotechnology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 19
States / cities: Bakersfield, California • Beverly Hills, California • Huntington Beach, California + 16 more

Conditions: Macular Edema, Central Retinal Vein Occlusion
Interventions: Ozurdex, Ranibizumab, Combination Ozurdex with Ranibizumab PRN; Drug
Lead sponsor: Valley Retina Institute; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 5
States / cities: Beverly Hills, California • Lakeland, Florida • Winter Haven, Florida + 2 more

Conditions: Diabetic Retinopathy
Interventions: Aflibercept Injection; Drug
Lead sponsor: Greater Houston Retina Research; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 2
States / cities: Houston, Texas • The Woodlands, Texas

Conditions: Diabetic Macular Edema
Interventions: Iluvien 0.19 MG Drug Implant, Aflibercept; Drug
Lead sponsor: Alimera Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 40
States / cities: Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 36 more

Conditions: Retinopathy of Prematurity
Interventions: Bevacizumab; Drug
Lead sponsor: Vision Research Foundation; Other
Eligibility: 30 Weeks to 36 Weeks
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 18
States / cities: Los Angeles, California • Palo Alto, California • Miami, Florida + 14 more

Conditions: Macular Edema, Diabetic Macular Edema, Neovascular Age-related Macular Degeneration, Retinal Vein Occlusion
Interventions: MHU650; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 5
States / cities: Huntington Beach, California • Honolulu, Hawaii • Hagerstown, Maryland + 2 more

Conditions: Diabetes Mellitus, Diabetic Retinopathy
Interventions: Implementation of Proactive Diabetes Eye Care Program; Behavioral
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: Not listed
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 3
States / cities: West Los Angeles, California • Ann Arbor, Michigan • Cleveland, Ohio

Conditions: Anterior Uveitis (AU), Birdshot Chorioretinitis, Behcet Disease, Herpes Simplex Virus, Juvenile Idiopathic Arthritis (JIA), Spondyloarthritis (SA), Sarcoidosis, Posterior Vitreous Detachment
Interventions: Not listed
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 5 Years to 85 Years
Enrollment: 125 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Diabetic Retinopathy, NPDR - Non Proliferative Diabetic Retinopathy
Interventions: VX-01, Placebo; Drug
Lead sponsor: Vantage Biosciences Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 9
States / cities: Beverly Hills, California • Palo Alto, California • Santa Barbara, California + 6 more

Conditions: Diabetic Retinopathy, Macular Edema
Interventions: MK-8748, Aflibercept; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 960 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 29
States / cities: Gilbert, Arizona • Glendale, California • Sacramento, California + 26 more

Conditions: Coat's Disease
Interventions: anecortave acetate; Drug
Lead sponsor: Manhattan Eye, Ear & Throat Hospital; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 1
States / cities: New York, New York

Conditions: Diabetic Macular Edema, Diabetic Retinopathy
Interventions: MS-R001 (rapamycin); Drug
Lead sponsor: Santen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 2
States / cities: Phoenix, Arizona • Arlington, Texas

Conditions: Glaucoma
Interventions: Dorzolamide 2%-timolol 0.5%, Brimonidine 0.2%-0.5% timolol 0.5; Drug
Lead sponsor: Massachusetts Eye and Ear Infirmary; Other
Eligibility: 40 Years to 80 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Diabetic Retinopathy
Interventions: Peribulbar Triamcinolone Acetonide; Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: Not listed
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Branch Retinal Vein Occlusion
Interventions: Macular Laser Photocoagulation, Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321); Procedure · Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 45
States / cities: Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 42 more

Conditions: Irvine-Gass Syndrome
Interventions: Aflibercept; Drug
Lead sponsor: Tufts Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

A Study of the Efficacy and Safety of KUS121 in Participants With Acute Non-Arteritic Central Retinal Artery Occlusion (CRAO)

Quest to Analyze One Thousand Humans Meditating

NVAMD Satellite Study

Ranibizumab Injections to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome

Open Label Study to Assess the Efficacy and Safety of AKB-9778 in Subjects With Macular Edema Due to RVO

Bevacizumab Versus Ranibizumab in Treatment of Macular Edema From Vein Occlusion

Resistance to Antibiotics in Patients Receiving Eye Injections

A Study Assessing AR-13503 Implant in Subjects With nAMD or DME

Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With DME (ASPIRE)

Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Occlusion

Intravitreal Aflibercept as Indicated by Real-Time Objective Imaging to Achieve Diabetic Retinopathy Improvement

A Study of Intravitreal ILUVIEN® Implant as Baseline Therapy in Patients With Early Diabetic Macular Edema (DME)

Pan-VEGF Blockade for the Treatment of Retinopathy of Prematurity (BLOCK-ROP)

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of IVT MHU650 in Macular Edema Patients

Study to Evaluate the Effectiveness of a Program Developed to Improve Eye Care for Veterans With Diabetes

Quantification & Classification of Inflammatory Cells in Uveitis Using OCT

A Study to Evaluate the Efficacy and Safety of Orally Administered VX-01

A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004)

Treatment of Congenital Telangiectasia (Coat's Disease) With Open-label Anecortave Acetate (15mg.)

Safety and Tolerability of MS-R001 in Patients With Diabetic Macular Edema Secondary to Diabetic Retinopathy

Effect of Cosopt Versus Combigan on Retinal Vascular Autoregulation in Primary Open Angle Glaucoma (POAG)

Triamcinolone Acetonide Injections to Treat Diabetic Macular Edema

Study to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in Patients With Branch Retinal Vein Occlusion (BRVO)

Treatment of Macular Edema After Cataract Surgery with Subconjunctival Aflibercept